Mapi integrates Epidemiology, HEOR and Strategic Market Access into Real World Strategy and Analytics
YARDLEY, Pa., July 20, 2015 /PRNewswire/ -- Mapi, the leading Commercialization and Health Research company, strengthens their global research and consulting services by integrating Mapi's Epidemiology and Risk Management, HEOR and Strategic Market Access teams with the expanded breadth of HEOR capabilities from a previously announced acquisition.
Mapi Group appoints Terri Madison, PhD, MPH to Sr. Vice President and Head, Real World Strategy & Analytics. Mapi, the leading Commercialization and Health Research company, strengthens their global research and consulting services by integrating Mapi's Epidemiology and Risk Management, HEOR and Strategic Market Access teams with the expanded breadth of HEOR capabilities from a previously announced acquisition.The newly integrated Real World Strategy and Analytics group is led by Dr. Terri Madison and is home to industry leading experts in establishing evidence development and dissemination strategy, where services support a holistic, integrated outcomes strategy encompassing safety, effectiveness, and economic endpoints. By directly connecting evidence development strategy, epidemiology, evidence synthesis and communication, Mapi offers innovative health research programs that leverage existing retrospective data and literature resources, supplemented with robust patient and provider-focused primary research, to support strategic market access, payer and clinician communications.
"The integration of these industry leading experts aligns with Mapi's growth strategy and the increasing demand from our client base as they seek to balance their commercialization requirements with the increasing need for experienced professionals," said James Karis, Mapi's Chief Executive Officer. "As today's novel therapeutics enter into a dynamic and crowded treatment field, only Mapi has the expertise to support market access and treatment adoption in complex markets with the most experienced and industry's largest dedicated Phase IV research team and Real World Evidence experts."
Dr. Madison is a seasoned professional with over 25 years of industry experience using evidence-based science and risk management methods to reinforce the benefit-risk profile of biopharmaceutical products. Dr. Madison previously served as Vice President, Epidemiology and Risk Management at Xcenda, as President of i3 Drug Safety, and as Chief Operating Officer at STATPROBE.
About Mapi:
Mapi Group has over 40 years of experience supporting Life-Science companies in utilizing Patient Reported Outcomes measures, Value communications and Health Economics and Outcomes Research, Strategic Regulatory Services, Pharmacovigilance, Health Research, Language Services, and gathering Real-World Evidence on Pharmaceuticals, Biologicals, and Medical Devices. Mapi Group is the premier provider of Health Research and Commercialization services to Life-Science companies enabling Market Authorization, Market Access and Market Adoption of novel therapeutics. Visit http://www.mapigroup.com for more information.
Press contact: [email protected]
Mapi Group
RSS